Literature DB >> 36107291

Inhibitory effects of Hydrocotyle ramiflora on testosterone-induced benign prostatic hyperplasia in rats.

Suyoung Park1, Youn-Hwan Hwang2, Eun-Bok Baek1, Eun-Ju Hong1, Young-Suk Won3, Hyo-Jung Kwun4.   

Abstract

PURPOSE: Benign prostatic hyperplasia (BPH) is a urogenital disorder that affects approximately 85% of males who are over 50 years of age. Hydrocotyle ramiflora (HR), belonging to Apiaceae family, is used to treat urinary system diseases such as urine retention in traditional Chinese herbal medicine. In this study, we evaluated the effects of HR in the BPH animal model.
METHODS: We induced BPH in rats via subcutaneous (sc) injections of testosterone propionate (TP, 3 mg/kg). Rats were also administered HR (150 mg/kg), finasteride (10 mg/kg), or vehicle via oral gavage. After induction, prostate glands were collected, weighed, and processed for further analysis, including histopathological examination and immunohistochemistry. In addition, the mRNA expression of inflammatory cytokines in prostatic tissues was determined by quantitative real-time PCR (qRT-PCR). The protein expression of pro-apoptotic markers was examined using western blotting.
RESULTS: HR treatment significantly reduced the prostate weight, epithelial thickness, and proliferating cell nuclear antigen (PCNA) expression, with the levels of cleaved caspase-3 and Bcl-2-associated X (Bax) protein considerably increased compared to BPH group. HR also decreased inflammatory cell infiltration and pro-inflammatory cytokine levels compared with BPH group. Furthermore, the expression of phosphor-nuclear factor-κB (NF-κB), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) were reduced by HR treatment.
CONCLUSION: These results indicate that HR suppresses the development of BPH associated with anti-proliferative, pro-apoptotic, and anti-inflammatory effects, suggesting it is a potential alternative therapeutic agent for BPH.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Apoptosis; Benign prostatic hyperplasia; Hydrocotyle ramiflora; Inflammation; Proliferation

Year:  2022        PMID: 36107291     DOI: 10.1007/s11255-022-03362-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  37 in total

Review 1.  The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).

Authors:  Giorgio Gandaglia; Alberto Briganti; Paolo Gontero; Nicola Mondaini; Giacomo Novara; Andrea Salonia; Alessandro Sciarra; Francesco Montorsi
Journal:  BJU Int       Date:  2013-04-12       Impact factor: 5.588

2.  Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.

Authors:  Charith Ub Wijerathne; Hee-Seon Park; Hye-Yun Jeong; Ji-Won Song; Og-Sung Moon; Young-Won Seo; Young-Suk Won; Hwa-Young Son; Jong-Hwan Lim; Sung-Hum Yeon; Hyo-Jung Kwun
Journal:  Biol Pharm Bull       Date:  2017-09-22       Impact factor: 2.233

3.  Evaluation of the resistive index of prostatic blood flow in benign prostatic hyperplasia.

Authors:  Osama Abdelwahab; Ehab El-Barky; Mostafa Mahmoud Khalil; Ahmad Kamar
Journal:  Int Braz J Urol       Date:  2012 Mar-Apr       Impact factor: 1.541

4.  Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40-79 years.

Authors:  Chun-Hou Liao; Hung-Yuan Li; Shiu-Dong Chung; Han-Sun Chiang; Hong-Jeng Yu
Journal:  Aging Male       Date:  2011-01-19       Impact factor: 5.892

5.  Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study.

Authors:  Henry A Feldman; Christopher Longcope; Carol A Derby; Catherine B Johannes; Andre B Araujo; Andrea D Coviello; William J Bremner; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 6.  Correlation between benign prostatic hyperplasia and inflammation.

Authors:  Yakup Bostanci; Amir Kazzazi; Shabnam Momtahen; Juliana Laze; Bob Djavan
Journal:  Curr Opin Urol       Date:  2013-01       Impact factor: 2.309

Review 7.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Gerald Andriole; Nicholas Bruchovsky; Leland W K Chung; Alvin M Matsumoto; Roger Rittmaster; Claus Roehrborn; David Russell; Donald Tindall
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

8.  Altered metabolism of androgens in elderly men with benign prostatic hyperplasia.

Authors:  T Ishimaru; L Pages; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

Review 9.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

10.  Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction.

Authors:  Nishant D Patel; J Kellogg Parsons
Journal:  Indian J Urol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.